Last updated date
ABOUT THIS STUDY
This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in
which subjects will use the product after making a purchase decision about ibuprofen 400 mg
caplets based only on their reading of the Drug Facts Label (DFL) and other information on
the package.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Patient Compliance
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Male or female at least 18 years of age (19 years of age in Alabama)
- Subject reports taking over-the-counter (OTC) analgesics for pain or fever relief
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Current government-issued identification (ID)
- Pregnant or breastfeeding females
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Patient ComplianceActual Use Trial of Ibuprofen 400 mg
NCT02294019
- Hoover, Alabama
- McCalla, Alabama
- Mesa, Arizona
- Fort Lauderdale, Florida
- Pembroke Pines, Florida
- Riverview, Florida
- Dalton, Georgia
- Griffin, Georgia
- Andover, Minnesota
- Anoka, Minnesota
- Blaine, Minnesota
- Elk River, Minnesota
- St. Louis Park, Minnesota
- Kansas City, Missouri
- Savannah, Missouri
- Monroe, New Jersey
- Albuquerque, New Mexico
- Taos, New Mexico
- Cary, North Carolina
- Bethlehem, Pennsylvania
- Bountiful, Utah
- Layton, Utah
- West Jordan, Utah
- Enumclaw, Washington
- Kenmore, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Actual Use Trial of Ibuprofen 400 mg | |||
| Official Title ICMJE | A Multicenter Actual Use And Compliance Study Of Ibuprofen 400 Mg In A Simulated Over-the-counter Environment | |||
| Brief Summary | This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in which subjects will use the product after making a purchase decision about ibuprofen 400 mg caplets based only on their reading of the Drug Facts Label (DFL) and other information on the package. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Masking: None (Open Label) | |||
| Condition ICMJE | Patient Compliance | |||
| Intervention ICMJE | Drug: Ibuprofen 400 mg caplet
400 milligram (mg) caplet according to Drug Facts label | |||
| Study Arms ICMJE | Experimental: Ibuprofen caplet arm
Intervention: Drug: Ibuprofen 400 mg caplet | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 738 | |||
| Original Estimated Enrollment ICMJE | 730 | |||
| Actual Study Completion Date ICMJE | May 2015 | |||
| Actual Primary Completion Date | May 2015 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT02294019 | |||
| Other Study ID Numbers ICMJE | B3491013 AUT ( Other Identifier: Alias Study Number ) | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | April 2016 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||